ReviewLung2026
Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives.
Review in Lung, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background and purposeLung cancer is the most frequently diagnosed malignancy worldwide in recent decades, representing the leading cause of cancer-related mortality globally. Lung cancer is mainly divided into two types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC being the most common, representing about 85% of cases. NSCLC is increasingly recognized to harbor various druggable genetic alterations; among them, activating BRAF mutations are found in approximately 3-4% of NSCLC patients. The objective of this review is to provide a comprehensive overview of the key biological and pathophysiological characteristics of BRAF molecular alterations, their impact on clinical practice, and emerging insights from translational research.
methodsWe performed a search of the PubMed database on April 22, 2026. A review of retrieved literature related to BRAF mutations and their clinical implications in NSCLC was completed. The Catalogue of Somatic Mutation in Cancer (COSMIC) database and the NCCN-NSCLC Guidelines were evaluated.
resultsFunctional classification of BRAF genetic alterations, molecular assays for detection of BRAF gene mutation, advancements of targeted therapies and immunotherapy for BRAF‑mutant NSCLC, and treatment resistance mechanisms were described. Several ongoing studies currently evaluating novel agents with broader biological activity and various drug combinations were reported. Emerging strategies-including next-generation MAPK inhibitors, ADCs, and engineered cellular therapies-were discussed, offering promising avenues to enhance efficacy, overcome resistance, and expand therapeutic options for these patients.
conclusionDespite limited clinical data, particularly in first line and neoadjuvant settings, remain major challenges, addressing critical questions will be useful to optimize the management of BRAF-mutant NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.